Published in Am J Hematol on January 09, 2012
Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood (2014) 0.96
Update on the use of hydroxyurea therapy in sickle cell disease. Blood (2014) 0.93
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database Syst Rev (2013) 0.87
A biopsychosocial model for the management of patients with sickle-cell disease transitioning to adult medical care. Adv Ther (2015) 0.80
Arterial ischemic stroke in children: risk factors and etiologies. Curr Neurol Neurosci Rep (2014) 0.75
Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev (2017) 0.75
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet (2011) 7.30
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med (2007) 6.76
Improved survival of children and adolescents with sickle cell disease. Blood (2010) 3.30
Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med (2014) 3.25
Survival of children with sickle cell disease. Blood (2004) 2.84
Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr (2004) 2.65
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood (2003) 2.55
Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol (2010) 2.55
The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer (2010) 2.36
Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood (2010) 2.25
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood (2012) 2.18
Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood (2010) 2.15
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J (2007) 2.14
Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood (2007) 2.13
Design and rationale of a randomized trial comparing the Blalock-Taussig and right ventricle-pulmonary artery shunts in the Norwood procedure. J Thorac Cardiovasc Surg (2008) 2.12
Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr (2003) 2.11
A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola. Am J Hematol (2013) 2.06
R2* magnetic resonance imaging of the liver in patients with iron overload. Blood (2009) 2.05
Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr (2003) 2.00
Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huët anomaly). Nat Genet (2002) 1.99
Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood (2005) 1.99
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer (2011) 1.89
In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology. J Clin Invest (2011) 1.89
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol (2007) 1.77
Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatr Blood Cancer (2010) 1.75
Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) (2004) 1.67
Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood (2012) 1.66
Day hospital versus inpatient management of uncomplicated vaso-occlusive crises in children with sickle cell disease. Pediatr Blood Cancer (2008) 1.62
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol (2006) 1.62
Arterial spin-labeled perfusion combined with segmentation techniques to evaluate cerebral blood flow in white and gray matter of children with sickle cell anemia. Pediatr Blood Cancer (2009) 1.60
Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. Am J Physiol Cell Physiol (2013) 1.56
Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. Blood (2011) 1.54
Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood (2002) 1.52
Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood (2013) 1.52
Outcomes for children with gallbladder abnormalities and sickle cell disease. J Pediatr (2004) 1.52
Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer (2005) 1.51
A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer (2009) 1.50
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol (2013) 1.49
Effect of oral arginine supplementation on exhaled nitric oxide concentration in sickle cell anemia and acute chest syndrome. J Pediatr Hematol Oncol (2010) 1.49
Classification of acute decompensated heart failure: an automated algorithm compared with a physician reviewer panel: the Atherosclerosis Risk in Communities study. Circ Heart Fail (2013) 1.47
Bone marrow transplant options and preferences in a sickle cell anemia cohort on chronic transfusions. Pediatr Blood Cancer (2012) 1.46
Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant (2009) 1.46
Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am (2008) 1.43
Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion (2013) 1.43
Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. Blood (2007) 1.43
Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood (2012) 1.43
Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program (2009) 1.40
R2* imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging (2007) 1.38
Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood (2005) 1.37
Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood (2011) 1.37
Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood (2012) 1.37
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia. Blood (2006) 1.31
Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol (2004) 1.30
Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer (2008) 1.30
Hemozoin-generated vapor nanobubbles for transdermal reagent- and needle-free detection of malaria. Proc Natl Acad Sci U S A (2013) 1.28
Healthcare utilization and expenditures for low income children with sickle cell disease. Pediatr Blood Cancer (2009) 1.28
Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood (2011) 1.26
Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood (2011) 1.25
Prolonged QTc interval in children and young adults with sickle cell disease at steady state. Pediatr Blood Cancer (2009) 1.25
Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res (2010) 1.24
Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol (2011) 1.19
Impact of differential attrition on the association of education with cognitive change over 20 years of follow-up: the ARIC neurocognitive study. Am J Epidemiol (2014) 1.18
Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol (2011) 1.18
Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children. Ann Surg (2003) 1.18
Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica (2010) 1.16
Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. Pediatr Nephrol (2011) 1.14
Acute silent cerebral ischemia and infarction during acute anemia in children with and without sickle cell disease. Blood (2012) 1.13
Genetic predictors for stroke in children with sickle cell anemia. Blood (2011) 1.12
Adherence to study medication and visits: data from the BABY HUG trial. Pediatr Blood Cancer (2010) 1.12
Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood (2012) 1.12
Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients. Br J Haematol (2009) 1.12
Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. Cancer (2011) 1.11
Pain as an emergent issue in thalassemia. Am J Hematol (2010) 1.10
Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica (2010) 1.10
Treatment of uncomplicated vaso-occlusive crises in children with sickle cell disease in a day hospital. Pediatr Blood Cancer (2008) 1.07
Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr (2002) 1.07